BIENAIME JEAN JACQUES purchased $204K of IMNM
BIENAIME JEAN JACQUES purchased 10,500 shares of Immunome Inc. (IMNM) at an average of $19.45 ($19.27–$19.48, $0.20M total) across 3 trades on 2026-06-05.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market purchase amount, price range, and post-transaction holdings; it may modestly influence sentiment but does not introduce new business fundamentals.
Market read
Traders may treat the filing as a small sentiment input, but without accompanying operational updates it is unlikely to drive a sustained repricing.
What to watch
No 10b5-1 plan is cited, but the article also lacks context on prior trading patterns, option exercises, or whether the director’s purchase is part of a broader accumulation strategy.
Background
The article summarizes an SEC Form 4 insider transaction for Immunome Inc. (IMNM).
Ticker impact
Immunome (IMNM) disclosed via SEC Form 4 that director Bienaime Jean Jacques bought 10,500 shares in open-market trades on 2026-06-05.
Likely limited/short-lived impact; any effect is more sentiment/positioning than a re-rating catalyst.
The filing is a primary-source insider transaction, but the article provides no new company fundamentals (no trial, revenue, or regulatory update).
Market effects
Minimal; this is company-specific insider activity with no sector-wide policy/clinical/regulatory signal.
None indicated.
None indicated.
Counterpoint
Insider buys can be routine (e.g., liquidity needs, diversification, or non-informational timing) and may not reflect near-term operational improvements.
Key entities
- issuerImmunome Inc.
Company subject of the SEC Form 4 insider transaction disclosure.
- insiderBIENAIME JEAN JACQUES
Director who purchased 10,500 shares across three open-market trades on 2026-06-05.